<DOC>
	<DOCNO>NCT00939874</DOCNO>
	<brief_summary>The purpose study determine low bone mineral density ( measurement thick strong bone ) improve adults HIV infection switch HIV medication tenofovir another HIV medication raltegravir . Hypothesis : That Bone Mineral Density ( BMD ) improve osteopenic osteoporotic patient switch ART include tenofovir disoproxil fumarate ( TDF ) ritonavir-boosted protease inhibitor ( r/PI ) ART include RAL+r/PI .</brief_summary>
	<brief_title>Switch From Tenofovir Raltegravir Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. provision write , inform consent 2 . HIVinfected adult least 18 year age 3. receive stable ART include TDF r/PI previous 6 month 4. prior PI genotypic resistance know replication HIV patient receive PI 5. plasma HIV RNA &lt; 50 copies/ml least previous 3 month 6. spine neck femur tscore â‰¤ 1.0 ( i.e . WHOdefined osteopenia ) measure dual energy xray absorptiometry ( DEXA ) 7. participation clinical trial ( unless approve study PI ) 8. use TDF previously active chronic hepatitis B infection 9. receive require therapy low BMD ( include prior fragility fracture ) 10. use oral corticosteroid inhale fluticasone 11. virological failure , intolerance , RAL 12. contraindication RAL therapy ( see appendix 2 ) 13. breastfeed 14. pregnancy 15. secondary , endocrinological cause low BMD:25hydroxy vitamin D deficiency , hypogonadism : ) symptomatic b ) asymptomatic define total testosterone &gt; 25 % low limit reference range and/or luteinizing hormone &gt; 2 x upper limit normal ( ULN ) , untreated hypothyroidism hyperparathyroidism accord local reference range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV+</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>osteopenia</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bone marker</keyword>
	<keyword>treatment experience</keyword>
</DOC>